180 related articles for article (PubMed ID: 16920097)
1. The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Rotondo S; Dell'Elba G; Manarini S; Cerletti C; Evangelista V
Eur J Pharmacol; 2006 Sep; 546(1-3):95-101. PubMed ID: 16920097
[TBL] [Abstract][Full Text] [Related]
2. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
Vidal C; Gómez-Hernández A; Sánchez-Galán E; González A; Ortega L; Gómez-Gerique JA; Tuñón J; Egido J
J Pharmacol Exp Ther; 2007 Jan; 320(1):108-16. PubMed ID: 17015640
[TBL] [Abstract][Full Text] [Related]
3. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
4. TxA2-mediated myocardial ischemia as a consequence of an acute lung inflammatory reaction in the rabbit.
Evangelista V; Dell'Elba G; Celardo A; Manarini S; Cerletti C
J Thromb Haemost; 2003 Feb; 1(2):314-9. PubMed ID: 12871506
[TBL] [Abstract][Full Text] [Related]
5. Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs.
Moreau M; Daminet S; Martel-Pelletier J; Fernandes J; Pelletier JP
J Vet Pharmacol Ther; 2005 Feb; 28(1):81-6. PubMed ID: 15720519
[TBL] [Abstract][Full Text] [Related]
6. Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity.
Hernandez MR; Tonda R; Pedreño J; Salas E; Arderiu G; Pino M; Serradell M; Escolar G
J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):859-65. PubMed ID: 17122671
[TBL] [Abstract][Full Text] [Related]
7. Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
Paredes Y; Massicotte F; Pelletier JP; Martel-Pelletier J; Laufer S; Lajeunesse D
Arthritis Rheum; 2002 Jul; 46(7):1804-12. PubMed ID: 12124864
[TBL] [Abstract][Full Text] [Related]
8. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.
Tavolari S; Bonafè M; Marini M; Ferreri C; Bartolini G; Brighenti E; Manara S; Tomasi V; Laufer S; Guarnieri T
Carcinogenesis; 2008 Feb; 29(2):371-80. PubMed ID: 18033773
[TBL] [Abstract][Full Text] [Related]
9. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Alvaro-Gracia JM
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i21-5. PubMed ID: 14752172
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
[TBL] [Abstract][Full Text] [Related]
11. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
Ulbrich H; Soehnlein O; Xie X; Eriksson EE; Lindbom L; Albrecht W; Laufer S; Dannhardt G
Biochem Pharmacol; 2005 Jul; 70(1):30-6. PubMed ID: 15894291
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological manipulation of inflammation in rabbit hydronephrosis: effects of a combined cyclooxygenase/lipoxygenase inhibitor ethoxyquin, a thromboxane synthase inhibitor RS-5186 and a PAF antagonist L-659,989.
Spaethe SM; Hsueh W; Needleman P
J Pharmacol Exp Ther; 1989 Mar; 248(3):1308-16. PubMed ID: 2539462
[TBL] [Abstract][Full Text] [Related]
13. Licofelone (Merckle).
Ding C; Cicuttini F
IDrugs; 2003 Aug; 6(8):802-8. PubMed ID: 12917777
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory effect of licofelone against various inflammatory challenges.
Singh VP; Patil CS; Kulkarni SK
Fundam Clin Pharmacol; 2006 Feb; 20(1):65-71. PubMed ID: 16448396
[TBL] [Abstract][Full Text] [Related]
15. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis.
Marcouiller P; Pelletier JP; Guévremont M; Martel-Pelletier J; Ranger P; Laufer S; Reboul P
J Rheumatol; 2005 Apr; 32(4):704-12. PubMed ID: 15801029
[TBL] [Abstract][Full Text] [Related]
16. Safety of anti-inflammatory treatment--new ways of thinking.
Brune K
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
[TBL] [Abstract][Full Text] [Related]
17. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.
Bias P; Buchner A; Klesser B; Laufer S
Am J Gastroenterol; 2004 Apr; 99(4):611-8. PubMed ID: 15089890
[TBL] [Abstract][Full Text] [Related]
18. The influence of acetylshikonin, a natural naphthoquinone, on the production of leukotriene B4 and thromboxane A2 in rat neutrophils.
Hsu MF; Chang LC; Huang LJ; Kuo SC; Lee HY; Lu MC; Wang JP
Eur J Pharmacol; 2009 Apr; 607(1-3):234-43. PubMed ID: 19232341
[TBL] [Abstract][Full Text] [Related]
19. Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function.
Rotondo S; Dell'Elba G; Krauze-Brzósko K; Manarini S; Martelli N; Pecce R; Evangelista V; Cerletti C
Eur J Pharmacol; 2002 Oct; 453(1):131-9. PubMed ID: 12393068
[TBL] [Abstract][Full Text] [Related]
20. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
Li L; Ji H; Sheng L; Zhang Y; Lai Y; Chen X
Eur J Pharmacol; 2009 Apr; 607(1-3):244-50. PubMed ID: 19243697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
